CFPAC-1 Xenograft Model Overview

The CFPAC-1 xenograft model is derived from a human pancreatic cancer cell line, CFPAC-1, established from a patient with pancreatic ductal adenocarcinoma (PDAC). PDAC is the most common and aggressive form of pancreatic cancer, known for its poor prognosis, rapid metastasis, and resistance to most conventional therapies. The CFPAC-1 xenograft model is widely used in preclinical research to study the biology of pancreatic cancer, including tumorigenesis, metastasis, and drug resistance mechanisms. This model is also valuable for evaluating therapeutic strategies targeting specific molecular pathways involved in pancreatic cancer progression and for testing novel chemotherapies and targeted treatments aimed at improving patient survival.

Request a Custom Quote for CFPAC-1 Xenograft Model

Biological and Molecular Characteristics

CFPAC-1 cells are characterized by their epithelial origin, expressing typical markers of pancreatic carcinoma, including cytokeratins and epithelial membrane antigen (EMA). The model has a mutated KRAS gene, which is present in over 90% of PDAC cases and is a key driver of tumorigenesis. Additionally, CFPAC-1 cells harbor inactivation of the tumor suppressor gene TP53, contributing to uncontrolled cell proliferation and resistance to apoptosis. The model also demonstrates dysregulated signaling pathways such as PI3K/AKT, which play a crucial role in promoting cell survival, growth, and metastasis. Given these molecular features, the CFPAC-1 xenograft model is particularly useful for testing new targeted therapies, chemotherapy agents, and combination treatments designed to overcome resistance mechanisms present in pancreatic cancer.

Marker	Expression Level	Function
Cytokeratin	High	Epithelial cell marker
EMA	High	Epithelial membrane antigen
KRAS	Mutated	Oncogene involved in tumor progression
TP53	Mutated	Tumor suppressor gene involved in apoptosis
PI3K/AKT pathway	Dysregulated	Promotes cell survival and proliferation

In Vivo Model Development and Tumorigenicity

The CFPAC-1 xenograft model is typically established by subcutaneously implanting CFPAC-1 cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Upon implantation, CFPAC-1 cells form rapidly growing tumors that closely mimic the clinical features of human pancreatic ductal adenocarcinoma, including high cellularity, necrosis, and significant vascularization. The model is used extensively to evaluate the effects of chemotherapy agents such as gemcitabine and cisplatin, which are commonly used in the treatment of pancreatic cancer. Due to its resistance to many chemotherapeutic agents, CFPAC-1 is an ideal model for studying chemotherapy resistance mechanisms and for testing new agents aimed at overcoming these challenges.

In addition to subcutaneous implantation, orthotopic implantation of CFPAC-1 cells into the pancreas of immunocompromised mice provides a more clinically relevant model. This orthotopic model allows for the study of tumor progression, metastasis, and local invasion, closely mimicking the natural course of pancreatic cancer in humans. The CFPAC-1 model is capable of metastasizing to distant organs such as the liver, lungs, and peritoneum, which provides an excellent platform for studying the metastatic behavior of pancreatic cancer and evaluating potential therapies to target metastasis.

Request a Custom Quote for CFPAC-1 Xenograft Model

Histopathology and Immunohistochemical Profile

Histopathological analysis of CFPAC-1 xenografts reveals the characteristic features of pancreatic ductal adenocarcinoma, including irregular glandular structures and areas of necrosis. The tumors are composed of pleomorphic cells with high mitotic activity and abundant cytoplasm, indicating rapid cell proliferation. Immunohistochemical staining of CFPAC-1 xenografts shows strong expression of epithelial markers, such as cytokeratins and EMA, confirming the epithelial origin of the tumor. Additionally, high levels of KRAS and phosphorylated AKT are observed, indicating the activation of critical signaling pathways involved in tumor survival and progression. The tumors also show significant vascularization, assessed using CD31 staining, reflecting the angiogenic activity that supports rapid tumor growth. Markers of immune evasion and stromal interactions are also present, making the model valuable for evaluating immunotherapies targeting the pancreatic tumor microenvironment.

Preclinical Applications and Drug Response

The CFPAC-1 xenograft model is widely used in preclinical studies to evaluate the efficacy of a variety of therapeutic agents for pancreatic cancer. Given its mutations in KRAS and TP53, the model is particularly valuable for testing new treatments that target these molecular alterations. CFPAC-1 tumors are sensitive to gemcitabine, a standard chemotherapy for PDAC, but can develop resistance over time, providing a useful system for studying chemotherapy resistance mechanisms and testing novel drugs to overcome these challenges.

The model is also used to evaluate targeted therapies aimed at the PI3K/AKT and MAPK/ERK pathways, which are often dysregulated in pancreatic cancer. Additionally, the CFPAC-1 xenograft is increasingly used to assess immunotherapies, including immune checkpoint inhibitors and CAR-T cell therapies, as PDAC is known for its immune-suppressive tumor microenvironment. Given its high metastatic potential, the CFPAC-1 model is ideal for studying therapies aimed at preventing or treating metastasis, one of the hallmarks of pancreatic cancer.

Request This Model

To request the CFPAC-1 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for CFPAC-1 Xenograft Model